Enabling implementation of Blood based biomarkers in our healthcare systems

The novel blood based biomarkers have shown such promising results, and these developments coincide with the approval of the first AD drugs. This needs to consider clinical implementation. Are we there yet? What steps need to be undertaken to make that happen? Can we implement these biomarkers, as single markers or as combinations in secondary care, primary care, or in‐between to avoid health care system overload?